The association of hormonal contraceptive use and HPV prevalence

International Journal of Cancer

Volumn 128, Issue 12, 2011, Pages 2962-2970

  Marks, Morgan ^a   Gravitt, Patti E ^a   Gupta, Swati B ^b   Liaw, Kai Li ^b   Kim, Esther ^a   Tadesse, Amha ^b   Phongnarisorn, Chailert ^c   Wootipoom, Virach ^d   Yuenyao, Pissamai ^e   Vipupinyo, Charoen ^f   Rugpao, Sungwal ^c   Sriplienchan, Somchai ^g   Celentano, David D ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c CHIANG MAI UNIVERSITY   (Thailand)

^d PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^e KHON KAEN UNIVERSITY   (Thailand)

^f RAJAVITHI HOSPITAL   (Thailand)

^g Faculty of Medicine Chiang Mai University   (Thailand)

Author keywords

COC; epidemiology; HPV; Thailand

Indexed keywords

ADULT; ARTICLE; CONTRACEPTION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; PAPILLOMAVIRUS INFECTION; PHYSICAL EXAMINATION; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; SEXUAL BEHAVIOR; SEXUAL INTERCOURSE; SEXUAL TRANSMISSION; THAILAND; UTERINE CERVIX CANCER; VIROLOGY; VIRUS STRAIN;

ADULT; ALPHAPAPILLOMAVIRUS; CONTRACEPTIVES, ORAL, HORMONAL; DNA, VIRAL; FEMALE; HUMANS;

EID: 79955392446     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25628     Document Type: Article

References (41)

1. Parkin DM, Bray F, Ferlay J, Pisani P,. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94: 153-6. (Pubitemid 32911406)
2. Munoz N, Bosch FX, de Sanjose S, Tafur L, Izarzugaza I, Gili M, Viladiu P, Navarro C, Martos C, Ascunce N, Gonzalez LC, Kaldor JM, Guerrero E, Lorincz A, Santamaria M, Alonso De Ruiz P, Aristizabal N, Shah K,. The causal link between human papillomavirus and invasive cervical cancer: a population-based case-control study in Colombia and Spain. Int J Cancer 1992; 52: 743-9.
3. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV, The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55: 244-65. (Pubitemid 34293391)
4. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N,. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-19. (Pubitemid 29406813)
5. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ,. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518-27. (Pubitemid 36159887)
6. Schiffman M, Herrero R, Desalle R, Hildesheim A, Wacholder S, Rodriguez AC, Bratti MC, Sherman ME, Morales J, Guillen D, Alfaro M, Hutchinson M, et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005; 337: 76-84. (Pubitemid 40725441)
7. Munoz N, Castellsague X, de Gonzalez AB, Gissmann L,. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006; 24 (Suppl 3): S1-S10. (Pubitemid 44293019)
8. Castellsague X, Munoz N,. Chapter 3: Cofactors in human papillomavirus carcinogenesis-role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr 2003; 31: 20-8.
9. Moreno V, Bosch FX, Munoz N, Meijer CJ, Shah KV, Walboomers JM, Herrero R, Franceschi S,. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet 2002; 359: 1085-92. (Pubitemid 34270731)
10. Appleby P, Beral V, Berrington de Gonzalez A, Colin D, Franceschi S, Goodhill A, Green J, Peto J, Plummer M, Sweetland S,. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet 2007; 370: 1609-21.
11. Smith JS, Green J, Berrington de Gonzalez A, Appleby P, Peto J, Plummer M, Franceschi S, Beral V,. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 2003; 361: 1159-67. (Pubitemid 36401593)
12. International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical carcinoma and reproductive factors: collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studies. Int J Cancer 2006; 119: 1108-24.
13. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA,. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003; 157: 218-26. (Pubitemid 36152435)
14. Moscicki AB, Hills N, Shiboski S, Powell K, Jay N, Hanson E, Miller S, Clayton L, Farhat S, Broering J, Darragh T, Palefsky J,. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 2001; 285: 2995-3002. (Pubitemid 32550118)
15. Sycuro LK, Xi LF, Hughes JP, Feng Q, Winer RL, Lee SK, O'Reilly S, Kiviat NB, Koutsky LA,. Persistence of genital human papillomavirus infection in a long-term follow-up study of female university students. J Infect Dis 2008; 198: 971-8.
16. Munoz N, Hernandez-Suarez G, Mendez F, Molano M, Posso H, Moreno V, Murillo R, Ronderos M, Meijer C, Munoz A,. Persistence of HPV infection and risk of high-grade cervical intraepithelial neoplasia in a cohort of Colombian women. Br J Cancer 2009; 100: 1184-90.
17. Castle PE, Wacholder S, Lorincz AT, Scott DR, Sherman ME, Glass AG, Rush BB, Schussler JE, Schiffman M,. A prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women. J Natl Cancer Inst 2002; 94: 1406-14. (Pubitemid 35154145)
18. Castle PE, Walker JL, Schiffman M, Wheeler CM,. Hormonal contraceptive use, pregnancy and parity, and the risk of cervical intraepithelial neoplasia 3 among oncogenic HPV DNA-positive women with equivocal or mildly abnormal cytology. Int J Cancer 2005; 117: 1007-12. (Pubitemid 41688578)
19. Deacon JM, Evans CD, Yule R, Desai M, Binns W, Taylor C, Peto J,. Sexual behaviour and smoking as determinants of cervical HPV infection and of CIN3 among those infected: a case-control study nested within the Manchester cohort. Br J Cancer 2000; 83: 1565-72.
20. Green J, Berrington de Gonzalez A, Smith JS, Franceschi S, Appleby P, Plummer M, Beral V,. Human papillomavirus infection and use of oral contraceptives. Br J Cancer 2003; 88: 1713-20. (Pubitemid 36760415)
21. Burk RD, Ho GY, Beardsley L, Lempa M, Peters M, Bierman R,. Sexual behavior and partner characteristics are the predominant risk factors for genital human papillomavirus infection in young women. J Infect Dis 1996; 174: 679-89. (Pubitemid 26325881)
22. Ley C, Bauer HM, Reingold A, Schiffman MH, Chambers JC, Tashiro CJ, Manos MM,. Determinants of genital human papillomavirus infection in young women. J Natl Cancer Inst 1991; 83: 997-1003.
23. Rousseau MC, Franco EL, Villa LL, Sobrinho JP, Termini L, Prado JM, Rohan TE,. A cumulative case-control study of risk factor profiles for oncogenic and nononcogenic cervical human papillomavirus infections. Cancer Epidemiol Biomarkers Prev 2000; 9: 469-76. (Pubitemid 30313889)
24. Kjaer SK, van den Brule AJ, Bock JE, Poll PA, Engholm G, Sherman ME, Walboomers JM, Meijer CJ,. Determinants for genital human papillomavirus (HPV) infection in 1000 randomly chosen young Danish women with normal Pap smear: are there different risk profiles for oncogenic and nononcogenic HPV types? Cancer Epidemiol Biomarkers Prev 1997; 6: 799-805. (Pubitemid 27435478)
25. Morrison CS, Richardson BA, Mmiro F, Chipato T, Celentano DD, Luoto J, Mugerwa R, Padian N, Rugpao S, Brown JM, Cornelisse P, Salata RA,. Hormonal contraception and the risk of HIV acquisition. AIDS 2007; 21: 85-95. (Pubitemid 44912541)
26. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, Raab S, Sherman M, Wilbur D, Wright T, Jr, Young N,. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002; 287: 2114-19. (Pubitemid 34437346)
27. Gravitt PE, Peyton CL, Alessi TQ, Wheeler CM, Coutlee F, Hildesheim A, Schiffman MH, Scott DR, Apple RJ,. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000; 38: 357-61. (Pubitemid 30043317)
28. Coutlee F, Gravitt P, Kornegay J, Hankins C, Richardson H, Lapointe N, Voyer H, Franco E,. Use of PGMY primers in L1 consensus PCR improves detection of human papillomavirus DNA in genital samples. J Clin Microbiol 2002; 40: 902-7. (Pubitemid 34208642)
29. Pearce N,. Effect measures in prevalence studies. Environ Health Perspect 2004; 112: 1047-50. (Pubitemid 39036126)
30. Zocchetti C, Consonni D, Bertazzi PA,. Relationship between prevalence rate ratios and odds ratios in cross-sectional studies. Int J Epidemiol 1997; 26: 220-3. (Pubitemid 27129588)
31. Thompson ML, Myers JE, Kriebel D,. Prevalence odds ratio or prevalence ratio in the analysis of cross sectional data: what is to be done? Occup Environ Med 1998; 55: 272-7. (Pubitemid 28179979)
32. Mitrani-Rosenbaum S, Tsvieli R, Tur-Kaspa R,. Oestrogen stimulates differential transcription of human papillomavirus type 16 in SiHa cervical carcinoma cells. J Gen Virol 1989; 70 (Part 8): 2227-32. (Pubitemid 19215129)
33. Mittal R, Tsutsumi K, Pater A, Pater MM,. Human papillomavirus type 16 expression in cervical keratinocytes: role of progesterone and glucocorticoid hormones. Obstet Gynecol 1993; 81: 5-12. (Pubitemid 23041694)
34. Marks M, Gravitt P, Burk R, Studentsov Y, Farzadegan H, Klein S,. Progesterone and 17b-estradiol enhance regulatory responses to HPV 16 VLP in peripheral blood mononuclear cells from healthy women. Clin Vaccine Immunol 2010; 17: 609-17.
35. Vaccarella S, Herrero R, Dai M, Snijders PJ, Meijer CJ, Thomas JO, Hoang Anh PT, Ferreccio C, Matos E, Posso H, de Sanjose S, Shin HR, et al. Reproductive factors, oral contraceptive use, and human papillomavirus infection: pooled analysis of the IARC HPV prevalence surveys. Cancer Epidemiol Biomarkers Prev 2006; 15: 2148-53. (Pubitemid 44877039)
36. Kjaer SK, Engholm G, Teisen C, Haugaard BJ, Lynge E, Christensen RB, MÃller KA, Jensen H, Poll P, Vestergaard BF, de Villiers EM, Jensen OM,. Risk factors for cervical human papillomavirus and herpes simplex virus infections in Greenland and Denmark: a population-based study. Am J Epidemiol 1990; 131: 669-82. (Pubitemid 20137235)
37. Lazcano-Ponce E, Herrero R, Munoz N, Cruz A, Shah KV, Alonso P, Hernandez P, Salmeron J, Hernandez M,. Epidemiology of HPV infection among Mexican women with normal cervical cytology. Int J Cancer 2001; 91: 412-20. (Pubitemid 32049638)
38. Peyton CL, Gravitt PE, Hunt WC, Hundley RS, Zhao M, Apple RJ, Wheeler CM,. Determinants of genital human papillomavirus detection in a US population. J Infect Dis 2001; 183: 1554-64. (Pubitemid 32466692)
39. Richardson H, Franco E, Pintos J, Bergeron J, Arella M, Tellier P,. Determinants of low-risk and high-risk cervical human papillomavirus infections in Montreal University students. Sex Transm Dis 2000; 27: 79-86. (Pubitemid 30082877)
40. Sukvirach S, Smith JS, Tunsakul S, Munoz N, Kesararat V, Opasatian O, Chichareon S, Kaenploy V, Ashley R, Meijer CJ, Snijders PJ, Coursaget P, et al. Population-based human papillomavirus prevalence in Lampang and Songkla, Thailand. J Infect Dis 2003; 187: 1246-56. (Pubitemid 36438965)
41. Shew ML, Fortenberry JD, Tu W, Juliar BE, Batteiger BE, Qadadri B, Brown DR,. Association of condom use, sexual behaviors, and sexually transmitted infections with the duration of genital human papillomavirus infection among adolescent women. Arch Pediatr Adolesc Med 2006; 160: 151-6. (Pubitemid 43213859)